Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Stefan Andreas. (2020) Effects of LAMA/LABA Alone and in Combination on Cardiac Safety. International Journal of Chronic Obstructive Pulmonary Disease 15, pages 1931-1933.
Read now
Read now
Stefan Andreas, Ulrich Bothner, Alberto de la Hoz, Isabel Kloer, Matthias Trampisch & Peter Alter. (2020) A Post Hoc Holter ECG Analysis of Olodaterol and Formoterol in Moderate-to-Very-Severe COPD. International Journal of Chronic Obstructive Pulmonary Disease 15, pages 1955-1965.
Read now
Read now
Stefan Andreas, Ulrich Bothner, Alberto de la Hoz, Isabel Kloer, Matthias Trampisch & Peter Alter. (2020) No Influence on Cardiac Arrhythmia or Heart Rate from Long-Term Treatment with Tiotropium/Olodaterol versus Monocomponents by Holter ECG Analysis in Patients with Moderate-to-Very-Severe COPD. International Journal of Chronic Obstructive Pulmonary Disease 15, pages 1945-1953.
Read now
Read now
Chenxi Li, Wenke Cheng, Jin Guo & Wei Guan. (2019) Relationship of inhaled long-acting bronchodilators with cardiovascular outcomes among patients with stable COPD: a meta-analysis and systematic review of 43 randomized trials. International Journal of Chronic Obstructive Pulmonary Disease 14, pages 799-808.
Read now
Read now
Paola Rogliani, Luigino Calzetta, Maria Gabriella Matera, Nicola di Daniele, Andrea Girolami, Mario Cazzola & Josuel Ora. (2019) Inhaled therapies and cardiovascular risk in patients with chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy 20:6, pages 737-750.
Read now
Read now
Andrea S. Melani. (2018) Olodaterol for the treatment of chronic obstructive pulmonary disease: a narrative review. Expert Opinion on Pharmacotherapy 19:14, pages 1603-1611.
Read now
Read now
Thomas J. Monaco & Nicola A. Hanania. (2017) Emerging inhaled long-acting beta-2 adrenoceptor agonists for the treatment of COPD. Expert Opinion on Emerging Drugs 22:3, pages 285-299.
Read now
Read now
Cristoforo Incorvaia, Marcello Montagni, Elena Makri, Gian Galeazzo Riario-Sforza & Erminia Ridolo. (2016) Striving for optimal bronchodilation: focus on olodaterol. International Journal of Chronic Obstructive Pulmonary Disease 11, pages 439-444.
Read now
Read now
Girolamo Pelaia, Alessandro Vatrella, Maria Teresa Busceti, Luca Gallelli, Cecilia Calabrese, Rosa Terracciano, Nicola Lombardo & Rosario Maselli. (2015) Pharmacologic rationale underlying the therapeutic effects of tiotropium/olodaterol in COPD. Therapeutics and Clinical Risk Management 11, pages 1563-1572.
Read now
Read now
Maria Gabriella Matera, Josuel Ora & Mario Cazzola. (2015) Differential pharmacology and clinical utility of long-acting bronchodilators in COPD – focus on olodaterol. Therapeutics and Clinical Risk Management 11, pages 1805-1811.
Read now
Read now
Wijdan H Ramadan, Wissam K Kabbara, Ghada M El Khoury & Sarah A Al Assir. (2015) Combined bronchodilators (tiotropium plus olodaterol) for patients with chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease 10, pages 2347-2356.
Read now
Read now
Articles from other publishers (16)
Cristina Rebordosa, Dóra Körmendiné Farkas, Jukka Montonen, Kristina Laugesen, Florian Voss, Jaume Aguado, Ulrich Bothner, Kenneth J. Rothman, Kristina Zint, Daniel Mines & Vera Ehrenstein. (2022) Cardiovascular events and all‐cause mortality in patients with chronic obstructive pulmonary disease using olodaterol and other long‐acting beta2‐agonists. Pharmacoepidemiology and Drug Safety 31:8, pages 827-839.
Crossref
Crossref
Gang Xing, Anthony Yiu-Ho Woo, Li Pan, Bin Lin & Mao-Sheng Cheng. (2020)
Recent Advances in β
2
-Agonists for Treatment of Chronic Respiratory Diseases and Heart Failure
. Journal of Medicinal Chemistry 63:24, pages 15218-15242.
Crossref
Crossref
Gary T. Ferguson, François Maltais, Jill Karpel, Ulrich Bothner, Isabel Kloer, Matthias Trampisch & Roland Buhl. (2020) Long-term safety of tiotropium/olodaterol in older patients with moderate-to-very-severe COPD in the TONADO® studies. npj Primary Care Respiratory Medicine 30:1.
Crossref
Crossref
Jinchun Wu, Yi Ye, Chenxi Li, Wenqin Zhou & Rong Chang. (2019) Correlation of Inhaled Long-Acting Bronchodilators With Adverse Cardiovascular Outcomes in Patients With Stable COPD. Journal of Cardiovascular Pharmacology 74:3, pages 255-265.
Crossref
Crossref
Chin Kook Rhee, Hajime Yoshisue & Rahul Lad. (2019) Fixed-Dose Combinations of Long-Acting Bronchodilators for the Management of COPD: Global and Asian Perspectives. Advances in Therapy 36:3, pages 495-519.
Crossref
Crossref
Gary T. Ferguson, Roland Buhl, Ulrich Bothner, Alberto de la Hoz, Florian Voß, Antonio Anzueto & Peter M.A. Calverley. (2018) Safety of tiotropium/olodaterol in chronic obstructive pulmonary disease: pooled analysis of three large, 52-week, randomized clinical trials. Respiratory Medicine 143, pages 67-73.
Crossref
Crossref
Stefan Andreas, Ulrich Bothner, Matthias Trampisch, Michaela Haensel, Roland Buhl & Peter Alter. (2018) Effect of long-acting β2-agonists olodaterol and formoterol on heart rate and blood pressure in chronic obstructive pulmonary disease patients. Pulmonary Pharmacology & Therapeutics 52, pages 1-6.
Crossref
Crossref
Andrea Koch, Henrik Watz, M. Reza Maleki-Yazdi, Ulrich Bothner, Kay Tetzlaff, Florian Voß & Lorcan McGarvey. (2017) Comprehensive assessment of the safety of olodaterol 5 µg in the Respimat® device for maintenance treatment of COPD: comparison with the long-acting β2-agonist formoterol. npj Primary Care Respiratory Medicine 27:1.
Crossref
Crossref
Hyun Woo Lee, Hyung-Jun Kim & Chang-Hoon Lee. (2017) The impact of olodaterol on the risk of mortality and serious adverse events: a systematic review and meta-analysis. British Journal of Clinical Pharmacology 83:6, pages 1166-1175.
Crossref
Crossref
Dave Singh, Giorgia Ciurlia, Annalisa Piccinno, Annamaria Muraro, Maria Bocchi & Mario Scuri. (2017) Acute cardiovascular safety of two formulations of beclometasone dipropionate/formoterol fumarate in COPD patients: A single-dose, randomised, placebo-controlled crossover study. Pulmonary Pharmacology & Therapeutics 42, pages 43-51.
Crossref
Crossref
Roland Buhl, Sheldon Magder, Ulrich Bothner, Kay Tetzlaff, Florian Voß, Lazaro Loaiza, Claus F. Vogelmeier & Lorcan McGarvey. (2017) Long-term general and cardiovascular safety of tiotropium/olodaterol in patients with moderate to very severe chronic obstructive pulmonary disease. Respiratory Medicine 122, pages 58-66.
Crossref
Crossref
M. Zysman, F. Chabot, P. Devillier, B. Housset, C. Morelot-Panzini & N. Roche. (2016) Pharmacological treatment optimization for stable chronic obstructive pulmonary disease. Proposals from the Société de Pneumologie de Langue Française. Revue des Maladies Respiratoires 33:10, pages 911-936.
Crossref
Crossref
Wijdan H. Ramadan, Wissam K. Kabbara & Rosa M. Abilmona. (2016) Olodaterol for the treatment of chronic obstructive pulmonary disease. American Journal of Health-System Pharmacy 73:15, pages 1135-1143.
Crossref
Crossref
Bryony Coupe, Andrew L. Griffiths & Gwyneth A. Davies. 2016. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions
153
164
.
Kai-Michael Beeh, Craig LaForce, Martina Gahlemann, Arne Wenz, Robert Toorawa & Matjaž Fležar. (2015) Randomised, double-blind, placebo-controlled crossover study to investigate different dosing regimens of olodaterol delivered via Respimat® in patients with moderate to severe persistent asthma. Respiratory Research 16:1.
Crossref
Crossref
Emma D. Deeks. (2015) Olodaterol: A Review of Its Use in Chronic Obstructive Pulmonary Disease. Drugs 75:6, pages 665-673.
Crossref
Crossref